Investigation of diagnosis at the early stage of biochemical hyperandrogenemia in women

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-DDT-14005186

Enrollment

Unknown

Registered

2014-09-05

Start date

2014-09-15

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome

Interventions

Gold Standard:

Index test:

Eligibility

Sex/Gender

Female

Age

15 Years to 45 Years

Inclusion criteria

Inclusion criteria: Aged 15-45 years, regular menses, no dysmenorrheal, no polycystic ovaries, their sisters had not been previously diagnosed with PCOS according to the Rotterdam criteria.

Exclusion criteria

Exclusion criteria: 1. Hyperprolactinemia: PRL more than 25 mg/L; 2. menopausal or pregnant women, FSH more than 40U/L; 3. clinical hyperandrogenemia, mFG more than 5 or biochemical hyperandrogenemia TT more than 2.6nmol/l (chemiluminescence) or F-T more than 6.6pg/ml (ELISA); 4. IFG (FPG=5.6mmol/l), IGT( PPG more than 7.8mmol/L) or HOMA-IR more than 2.14; 5. acanthosis nigricans (+); 6. Cushing syndrome; 7. CAH (congenital adrenal hyperplasia); 8. have taken medicines that may affect endocrine or metabolism (oral contraceptive or metformin) the recent 3 months.

Design outcomes

Primary

Measure	Time frame
testosterone;	—

Countries

China

Contacts

Public ContactXiaomiao Zhao

Sun Yat-Sen Memorial Hospital

zhaoxmiao@163.com+86 13922209605

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026